Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing oilseed Camelina to produce proprietary products; and high value seed traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.
IPO Year: 2006
Exchange: NASDAQ
Website: yield10bio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/8/2024 | Buy → Hold | Lake Street | |
| 3/10/2022 | $18.00 → $9.00 | Buy | Maxim Group |
8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
DEFM14A - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
PREM14A - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
10-Q - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
424B3 - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
EFFECT - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Willie Loh, Ph.D., was named to the Company's Board of Directors effective October 4, 2022. Dr. Loh previously served as a Special Commercial and Technical Advisor to the Company. Dr. Loh was formerly Vice President, Market Development of Cargill Inc.'s Global Edible Oils Solutions group in North America. Cargill is a global food and agriculture company. "We are delighted that Willie is expanding his role with Yield10 by serving on our Board of Directors," said Oliver Peoples, Ph.D., Chief Executive Officer of Yield1
Special Meeting Adjourned to Thursday, November 21, 2024 WOBURN, MA / ACCESSWIRE / November 8, 2024 / Yield10 Bioscience, Inc. (OTCQB:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that its Special Meeting of Stockholders (the "Special Meeting"), scheduled to be held at 11:00 a.m., Eastern Time, on November 8, 2024, was convened and adjourned, without any business being conducted, due to lack of sufficient votes in favor of the key proposals related to the Asset Sale to Nuseed and the Dissolution proposal.To pass the proposals, more than 50% of the shares of common stock outstanding and entitled to vote as of the close of business on October 3, 2024
WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. "We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our shareholders, business partners, and employees. Receipt of the initial $3 million payment and progress toward earning an additional $2 million milestone payment is enabling
WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina. Nufarm and Yield10 have additionally agreed to immediately negotiate exclusively with each other for the sale of Yield10's remaining assets to Nufarm. The asset sale will require an affirmative vote
- Nufarm to pay up to USD $5 million in consideration for the license-The parties will negotiate the sale of essentially all of Yield10's assets to Nufarm WOBURN, Mass. and WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina. Under the License Agreeme
WOBURN, Mass. and HARPENDEN, United Kingdom, June 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that U.K.-based Rothamsted Research Limited ("Rothamsted") has granted to the Company an exclusive global, commercial license to advanced technology for producing sustainable omega-3 products in Camelina sativa ("Camelina"). Yield10 is executing a plan to use engineered Camelina to commercially produce omega-3 oil and meal products targeting the aquafeed, petfood, and nutritional markets for omega-3 fatty acids. In consideration for the commercial license, Yield10 is expected to pay certain licen
- EPA approved an amendment to the label of INTERLINE herbicideto include Camelina -The supplemental label now allows application of INTERLINE for over-the-top weed control in Camelina WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that UPL Ltd. ("UPL") has received U.S. Environmental Protection Agency ("EPA") approval to amend the label language of INTERLINE® Herbicide to include the oilseed Camelina sativa ("Camelina"). This approval allows Yield10's glufosinate-tolerant Camelina to be sprayed with INTERLINE®, a glufosinate containing herbicide, providing farmers with
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first quarter ended March 31, 2024. "In the first quarter of 2024, we made the strategic decision to focus our resources on the commercialization of Camelina products targeting the aquafeed and nutritional markets for omega-3 fatty acids," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. "We are building seed inventory in anticipation of commercial scale planting, planning to obtain regulatory approval to sell omega-3 oil for aquafeed in Chile, and engaging with potenti
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder's equity of at least $2,500,000. Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on May 16, 2024. Following the N
WOBURN, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024. The 1-for-24 reverse stock split will be effective as of 5:00 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on Thursday, May 2, 2024, and the Company's common stock will begin trading on a split-adjusted basis on Friday, May 3, 2024. The reverse stock split will reduce the number of shares of the Company's
-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023. "In 2023 we successfully executed our plan and achieved several
Lake Street downgraded Yield10 Bioscience from Buy to Hold
Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $9.00 from $18.00 previously
Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $24.00 from $12.00 previously
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
Yield10 Bioscience (NASDAQ:YTEN) reported quarterly losses of $(4.77) per share which missed the analyst consensus estimate of $(2.64) by 80.68 percent. The company reported quarterly sales of $300.00 thousand which missed the analyst consensus estimate of $1.88 million by 84.00 percent. This is a 400.00 percent increase over sales of $60.00 thousand the same period last year.
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results. Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from Benzinga Pro. Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers AERWINS Technologies Inc. (NASDAQ:AWIN) shares surged
Gainers SINTX Techs (NASDAQ:SINT) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. Nutriband (NASDAQ:NTRB) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. Bone Biologics (NASDAQ:BBLG) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. OptimizeRx (NASDAQ:OPRX) shares moved upwards by 22.8% to $12.87. The market value of their
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Wednesday. Following the market opening, the Dow traded up 0.54% to 39,772.77 while the NASDAQ rose 0.57% to 5,276.57. The S&P 500 also rose, gaining, 0.59% to 16,608.83 . . Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Materials Stocks Delivering High-Dividend Yields Leading and Lagging SectorsReal estate shares rose by 1.8% on Wednesday. In trading on Wednesday, energy shares fell by 0.5%. Top Headline U.S. consumer prices rose 0.3% month-over-month in April compared to 0.4% in the previous month, and also dow
Patent Center (uspto.gov)
- SEC Filing
-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023. "In 2023 we successfully executed our plan and achieved several
WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024. Management will host a conference call on Monday, April 1, 2024.at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-877-709-8150 or +1-201-689-8354 (international) to listen to the call. Th
WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023. Management will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-800-715-9871 or +1-646-307-1963 (international) to listen to the call. The Conf
WOBURN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its second quarter 2023 financial results and provide a corporate update on Monday, August 14, 2023. Management will host a conference call on Monday, August 14, 2023 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. To listen to the conference call, interested parties within the U.S. should call 1-877-709-8150. International callers should
WOBURN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its first quarter 2023 financial results and provide a corporate update on Wednesday, May 10, 2023. Management will host a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. To listen to the conference call, interested parties within the U.S. should call 1-877-709-8150. International callers should c
-Executing strategy to build supply chain alliances for the production of low-carbonintensity Camelina feedstock oil for the biofuels market-Advancing development of herbicide tolerant Camelina varieties-Accelerating development of omega-3 Camelina -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2022. "Yield10 is building a diverse Camelina products business based on our di
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2022 financial results and provide a corporate update on Tuesday, March 14, 2023. Management will host a conference call on Tuesday, March 14, 2023 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. To listen to the conference call, interested parties within the U.S. should call 1-877-709-8150. International callers
WOBURN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its third quarter 2022 financial results and provide a corporate update on Monday, November 14, 2022. Management will host a conference call on Monday, November 14, 2022 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. To listen to the conference call, interested parties within the U.S. should call 1-800-715-9871. International callers
WOBURN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its second quarter 2022 financial results and provide a corporate update on Wednesday, August 10, 2022. Management will host a conference call on Wednesday, August 10, 2022 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. To listen to the conference call, interested parties within the U.S. should call 1-877-709-8150. International callers should c
WOBURN, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its first quarter 2022 financial results and provide a corporate update on Wednesday, May 11, 2022. Management will host a conference call on Wednesday, May 11, 2022 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. To listen to the conference call, interested parties within the U.S. should call 1-877-709-8150. International callers should call +1-2
SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)
SC 13D - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)
SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)
SC 13G/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)
SC 13G/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)
SC 13G/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)
SC 13G - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)